SPMS
MCID: SCN036
MIFTS: 56

Secondary Progressive Multiple Sclerosis (SPMS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 54 15 17
Multiple Sclerosis, Secondary Progressive 71
Multiple Sclerosis, Chronic Progressive 43
Chronic Progressive Multiple Sclerosis 17
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 43 D020528
UMLS 71 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to allergic encephalomyelitis and primary progressive multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is HNRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mitoxantrone and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and bone, and related phenotypes are homeostasis/metabolism and cellular

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 allergic encephalomyelitis 31.4 MBP CCL2
2 primary progressive multiple sclerosis 31.0 S100B MMP9 MBP IL4 IL10 IFNB1
3 exanthem 30.8 IL10 CD40LG ALB
4 encephalitis 30.7 IL10 CXCL10 CD40LG CCR5 CCL2
5 macular retinal edema 30.6 IFNB1 CCL2 ALB
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL17A IL10 IFNG
7 progressive multifocal leukoencephalopathy 30.6 MBP IFNB1 CD40LG
8 optic neuritis 30.5 MBP IL10 CXCR3 CXCL10 CCR5 BDNF
9 acute cystitis 30.5 IL10 CD40LG CCL2 ALB
10 pericarditis 30.5 IFNG CD40LG ALB
11 herpes zoster 30.4 IL10 IFNG CD40LG CCR5
12 chickenpox 30.3 IL4 IL10 IFNG CD40LG ALB
13 cutaneous t cell lymphoma 30.3 IL4 IFNG CXCR3 CXCL10
14 rubella 30.3 IL4 IL10 IFNG IFNB1 CD40LG
15 myelitis 30.2 MMP9 MBP IL17A IL10 IFNB1 CD40LG
16 viral meningitis 30.2 IFNG CXCR3 CXCL10 CD40LG CCL2
17 nervous system disease 30.2 MMP9 MBP IFNG CXCR3 BDNF ALB
18 tetanus 30.1 MBP IL4 IL10 IFNG CD40LG ALB
19 neuromyelitis optica 30.1 S100B MBP IL4 IL17A CXCL10 CD40LG
20 bacterial infectious disease 30.1 IL17A IL10 IFNG IFNB1 CD40LG CCL2
21 vascular disease 30.1 MMP9 IL10 IFNG CD40LG CCL2 ALB
22 arthritis 30.0 MMP9 IL4 IL17A IL10 IFNG CCR2
23 relapsing-remitting multiple sclerosis 29.9 NGF MMP9 MBP IL4 IL17A IL10
24 neuritis 29.9 MMP9 MBP IL4 IL10 IFNG CXCL10
25 cystitis 29.9 NGF IL4 IL17A CXCR3 CXCL10 CCL2
26 proteasome-associated autoinflammatory syndrome 1 29.8 MMP9 IL4 IL17A IL10 IFNG CXCL10
27 autoimmune disease 29.7 MMP9 MBP IL4 IL17A IL10 IFNG
28 inflammatory bowel disease 29.5 MMP9 IL4 IL17A IL10 IFNG CXCR3
29 demyelinating disease 29.2 NGF MMP9 MBP IL4 IL17A IL10
30 multiple sclerosis 28.8 NGF MMP9 MBP IL4 IL17A IL10
31 scapuloperoneal myopathy, x-linked dominant 11.6
32 scapuloperoneal myopathy 11.5
33 tropical endomyocardial fibrosis 10.7 IL4 IL10
34 riedel's fibrosing thyroiditis 10.7 CD40LG ALB
35 lentigo maligna melanoma 10.7 S100B MMP9
36 cork-handlers' disease 10.7 CD40LG ALB
37 acute transverse myelitis 10.7 MMP9 IL10
38 folliculotropic mycosis fungoides 10.7 CXCR3 CCR3
39 fournier gangrene 10.6 CD40LG ALB
40 nerve fibre bundle defect 10.6 CD40LG BDNF
41 chromoblastomycosis 10.6 MMP9 IL4 CXCR3
42 sydenham chorea 10.6 CXCL10 BDNF
43 parotitis 10.6 MMP9 CD40LG ALB
44 heterophyiasis 10.6 CD40LG ALB
45 neurosyphilis 10.6 IL17A IL10 CXCL10
46 metal allergy 10.6 IL4 IL17A IL10
47 palladium allergic contact dermatitis 10.6 IL17A IL10 CCL2
48 systemic autoimmune disease 10.6 MMP9 IL17A
49 inflammatory bowel disease 18 10.6 IL4 IL17A IL10
50 gingival disease 10.6 MMP9 IL17A IL10

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 ALB BDNF CCR2 CCR3 CCR5 CD40LG
2 cellular MP:0005384 10.35 ALB BDNF CCR2 CCR3 CCR5 CD40LG
3 immune system MP:0005387 10.35 ALB CCL2 CCR2 CCR3 CCR5 CD40LG
4 hematopoietic system MP:0005397 10.32 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
5 mortality/aging MP:0010768 10.28 ALB BDNF CCR2 CCR5 CD40LG CXCL10
6 cardiovascular system MP:0005385 10.25 ALB CCR2 CCR5 CD40LG CXCL10 CXCR3
7 digestive/alimentary MP:0005381 10.18 ALB BDNF CCR2 CCR5 IFNG IL10
8 nervous system MP:0003631 10.15 BDNF CCR2 CCR5 CD40LG CXCL10 IFNB1
9 integument MP:0010771 10.11 BDNF CD40LG IFNG IL10 IL17A IL4
10 neoplasm MP:0002006 10.01 ALB CCR2 CCR5 CXCR3 IFNB1 IFNG
11 normal MP:0002873 9.96 ALB BDNF CXCR3 IFNB1 IFNG IL10
12 no phenotypic analysis MP:0003012 9.92 BDNF CCR2 IFNB1 IFNG IL10 IL17A
13 renal/urinary system MP:0005367 9.76 ALB CCR2 CD40LG CXCR3 IFNG IL17A
14 respiratory system MP:0005388 9.61 BDNF CCR2 CCR3 CXCR3 IFNG IL10
15 vision/eye MP:0005391 9.28 BDNF CCR2 CCR5 IFNG IL10 IL4

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
3
Natalizumab Approved, Investigational Phase 4 189261-10-7
4
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6 Interferon-beta Phase 4
7 Topoisomerase Inhibitors Phase 4
8 Neurotransmitter Agents Phase 4
9 Melanocyte-Stimulating Hormones Phase 4
10 Adrenocorticotropic Hormone Phase 4
11 beta-endorphin Phase 4
12 Endorphins Phase 4
13 Hormones Phase 4
14 Anti-Inflammatory Agents Phase 4
15 glucocorticoids Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Hormone Antagonists Phase 4
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
20 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
22
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
23
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
24
Chlorpheniramine Approved Phase 2, Phase 3 132-22-9, 113-92-8 2725
25
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
26
Bortezomib Approved, Investigational Phase 3 179324-69-7 93860 387447
27
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
28
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
29
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
30
Morphine Approved, Investigational Phase 3 57-27-2 5288826
31
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
32
Promethazine Approved, Investigational Phase 3 60-87-7 4927
33
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
34
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
35
rituximab Approved Phase 3 174722-31-7 10201696
36
Carmustine Approved, Investigational Phase 3 154-93-8 2578
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
38
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
39
Melphalan Approved Phase 3 148-82-3 4053 460612
40
Mesna Approved, Investigational Phase 3 3375-50-6 598
41
Etoposide Approved Phase 3 33419-42-0 36462
42
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
43
Lenograstim Approved, Investigational Phase 3 135968-09-1
44
Ixazomib Approved, Investigational Phase 3 1072833-77-2
45
Histamine Approved, Investigational Phase 3 51-45-6 774
46
Lenalidomide Approved Phase 3 191732-72-6 216326
47
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
48
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
49
Epigallocatechin Experimental, Investigational Phase 2, Phase 3 970-74-1 72277
50
Epicatechin Investigational Phase 2, Phase 3 35323-91-2, 490-46-0 72276

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
2 An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
3 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
4 An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830 Completed NCT00915460 Phase 4 Interferon beta-1a (Avonex)
5 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
6 A Randomized, Single-Blind, Clinical Study to Assess Food Occlusion Efficacy of a Marketed Denture Adhesive in Healthy, Edentulous Subjects Completed NCT03709810 Phase 4
7 Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis Recruiting NCT03963375 Phase 4 Cladribine
8 Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS Recruiting NCT02446886 Phase 4 Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
9 Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Not yet recruiting NCT04178005 Phase 4 Cladribine
10 Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort Terminated NCT01411514 Phase 4 Prednisone;Placebo
11 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
12 A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Unknown status NCT02057159 Phase 2, Phase 3
13 Lipoic Acid for Neuroprotection in Secondary Progressive MS Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
14 A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
15 Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate Completed NCT03315923 Phase 2, Phase 3 Rituximab;Glatiramer Acetate
16 A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
17 A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3 placebo;rituximab
18 Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
19 A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension Completed NCT01917019 Phase 3 Placebo;BIIB041 (fampridine)
20 Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis Completed NCT02290444 Phase 3 Adrenocorticotropic Hormone
21 Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION) Completed NCT00813709 Phase 3 RNF;RNF;RNF;Placebo
22 Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT) Completed NCT02322320 Phase 3 Lenalidomide
23 A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC) Completed NCT00988208 Phase 3 Lenalidomide;Docetaxel;Prednisone;Placebo
24 A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability Recruiting NCT03387670 Phase 3 Simvastatin;Placebo
25 Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years Recruiting NCT03653273 Phase 3 DMT continuation
26 An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis Recruiting NCT02688985 Phase 3 Ocrelizumab;Methyloprednisolone;Antihistamine
27 A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Recruiting NCT04035005 Phase 3 Ocrelizumab;Placebo
28 A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714 Recruiting NCT03691077 Phase 3 Ocrelizumab
29 Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial Recruiting NCT02858258 Phase 3 R-CHOP/R-DHAP;Ibrutinib (Induction);ASCT conditioning;Ibrutinib (Maintenance)
30 A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Active, not recruiting NCT01433497 Phase 3 Masitinib;Placebo
31 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312. Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
32 A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3 Ocrelizumab
33 A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) Not yet recruiting NCT04047628 Phase 3
34 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients Not yet recruiting NCT03710655 Phase 3 Apitox - pure honeybee toxin;Placebo
35 Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I) Not yet recruiting NCT03720041 Phase 3 R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm;R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm;R2: Lenalidomide plus placebo maintenance;R2: Lenalidomide + ixazomib maintenance
36 A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
37 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension Terminated NCT01416181 Phase 3 natalizumab;Placebo
39 A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
40 An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
41 A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis Terminated NCT00731692 Phase 3 FTY720;Placebo
42 A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
43 A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. Unknown status NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
44 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
45 A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents Unknown status NCT00298662 Phase 2 Interferon beta-1b and Tacrolimus
46 A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination Unknown status NCT02149706 Phase 2
47 Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
48 Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2 Erythropoietin
49 A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
50 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

40
Brain, T Cells, Bone, B Cells, Spinal Cord, Thyroid, Testes

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 1731)
# Title Authors PMID Year
1
[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. 54 61
20443171 2010
2
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. 54 61
15645350 2004
3
Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. 61 54
9343121 1997
4
Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. 61
31509235 2020
5
Monitoring complexity and resilience in construction projects: The contribution of safety performance measurement systems. 61
31654953 2020
6
Promoting resolution in kidney disease: are we nearly there yet? 61
31599748 2020
7
Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. 61
30861567 2020
8
Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis. 61
31795956 2019
9
Osteosarcoma without prior retinoblastoma related to RB1 low-penetrance germline pathogenic variants: A novel type of RB1-related hereditary predisposition syndrome? 61
31568710 2019
10
Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. 61
31810488 2019
11
Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression. 61
31273563 2019
12
Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center. 61
31394007 2019
13
Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany. 61
31832974 2019
14
Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors. 61
31804055 2019
15
Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome. 61
31797565 2019
16
Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. 61
31832116 2019
17
Heme oxygenase-1/carbon monoxide as modulators of autophagy and inflammation. 61
31704095 2019
18
Fairweather Friends: Evidence of Lipoxin Dysregulation in Neurodegeneration. 61
31797529 2019
19
3D-Printed Scanning-Probe Microscopes with Integrated Optical Actuation and Read-Out. 61
31804019 2019
20
Correlation between LincR-Gng2-5'and LincR-Epas1-3'as with the severity of multiple sclerosis in Egyptian patients. 61
31790618 2019
21
Genetic Alterations in Patients with Two Clinical Phenotypes of Multiple Sclerosis. 61
31686392 2019
22
Impact of multiple sclerosis phenotypes on burden of disease in Finland. 61
31617776 2019
23
Antibodies from the Sera of Multiple Sclerosis Patients Efficiently Hydrolyze Five Histones. 61
31731780 2019
24
Prognostic impact of epilepsy in multiple sclerosis. 61
31726355 2019
25
Resolution of inflammation during multiple sclerosis. 61
31732775 2019
26
Multiple sclerosis in Finland 2018-Data from the national register. 61
31271648 2019
27
Diagnosis and management of secondary-progressive multiple sclerosis: time for change. 61
31769344 2019
28
B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review. 61
31775673 2019
29
Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. 61
31549947 2019
30
Spermidine application reduces fluoride uptake and ameliorates physiological injuries in a susceptible rice cultivar by activating diverse regulators of the defense machinery. 61
31734839 2019
31
Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. 61
31586800 2019
32
Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. 61
31693730 2019
33
Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis. 61
31500466 2019
34
Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. 61
31611336 2019
35
A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. 61
31768628 2019
36
DHA and its derived lipid mediators MaR1, RvD1 and RvD2 block TNF-α inhibition of intestinal sugar and glutamine uptake in Caco-2 cells. 61
31760230 2019
37
Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases. 61
31711309 2019
38
Specialized pro-resolving lipid mediators: A new class of non-immunosuppressive and non-opioid analgesic drugs. 61
31743775 2019
39
Maresin1 Decreased Microglial Chemotaxis and Ameliorated Inflammation Induced by Amyloid-β42 in Neuron-Microglia Co-Culture Models. 61
31796671 2019
40
The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis. 61
31450158 2019
41
Proresolving Mediators LXB4 and RvE1 Regulate Inflammation in Stromal Cells from Patients with Shoulder Tendon Tears. 61
31437425 2019
42
The Role of Maresins in Inflammatory Pain: Function of Macrophages in Wound Regeneration. 61
31766461 2019
43
Endogenous Specialized Proresolving Mediator Profiles in a Novel Experimental Model of Lymphatic Obstruction and Intestinal Inflammation in African Green Monkeys. 61
31547920 2019
44
Cardiac ALL: Most Unusual Occurrence of Lenalidomide-associated Acute Lymphoblastic Leukemia with Subsequent Cardiac Involvement. 61
31815073 2019
45
Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. 61
31251393 2019
46
Cognitive and brain reserve in multiple sclerosis--A cross-sectional study. 61
31374461 2019
47
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. 61
31573386 2019
48
Palliative care interventions for people with multiple sclerosis. 61
31637711 2019
49
Vitamin D and MRI measures in progressive multiple sclerosis. 61
31445221 2019
50
Is multiple sclerosis progression associated with the HLA-DR15 haplotype? 61
31839982 2019

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6 (show all 19) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HNRNPA1 NM_031157.4(HNRNPA1):c.997T>C (p.Phe333Leu)SNV Pathogenic 135600 rs483353031 12:54677685-54677685 12:54283901-54283901
2 HNRNPA1 NM_031157.4(HNRNPA1):c.973T>G (p.Phe325Val)SNV Pathogenic 135595 rs483353028 12:54677661-54677661 12:54283877-54283877
3 HNRNPA1 NM_031157.4(HNRNPA1):c.973T>C (p.Phe325Leu)SNV Pathogenic 135594 rs483353028 12:54677661-54677661 12:54283877-54283877
4 HNRNPA1 NM_031157.4(HNRNPA1):c.987G>T (p.Lys329Asn)SNV Likely pathogenic 135598 rs483353030 12:54677675-54677675 12:54283891-54283891
5 HNRNPA1 NM_031157.4(HNRNPA1):c.979C>T (p.Pro327Ser)SNV Likely pathogenic 135596 rs483353029 12:54677667-54677667 12:54283883-54283883
6 HNRNPA1 NM_031157.4(HNRNPA1):c.1058A>G (p.Asn353Ser)SNV Likely pathogenic 135608 rs483353038 12:54677746-54677746 12:54283962-54283962
7 HNRNPA1 NM_031157.4(HNRNPA1):c.1057A>G (p.Asn353Asp)SNV Likely pathogenic 135607 rs483353039 12:54677745-54677745 12:54283961-54283961
8 HNRNPA1 NM_031157.4(HNRNPA1):c.943T>C (p.Phe315Leu)SNV Likely pathogenic 135592 rs483353022 12:54677631-54677631 12:54283847-54283847
9 HNRNPA1 NM_031157.4(HNRNPA1):c.949A>G (p.Asn317Asp)SNV Likely pathogenic 135593 rs483353023 12:54677637-54677637 12:54283853-54283853
10 HNRNPA1 NM_031157.4(HNRNPA1):c.1052C>T (p.Pro351Leu)SNV Likely pathogenic 135605 rs483353036 12:54677740-54677740 12:54283956-54283956
11 HNRNPA1 NM_031157.4(HNRNPA1):c.1042T>C (p.Phe348Leu)SNV Likely pathogenic 135604 rs483353035 12:54677730-54677730 12:54283946-54283946
12 HNRNPA1 NM_031157.4(HNRNPA1):c.1040A>G (p.Tyr347Cys)SNV Likely pathogenic 135603 rs483353034 12:54677728-54677728 12:54283944-54283944
13 HNRNPA1 NM_031157.4(HNRNPA1):c.1009A>G (p.Ser337Gly)SNV Likely pathogenic 135602 rs483353033 12:54677697-54677697 12:54283913-54283913
14 HNRNPA1 NM_031157.4(HNRNPA1):c.1006A>G (p.Arg336Gly)SNV Likely pathogenic 135601 rs483353032 12:54677694-54677694 12:54283910-54283910
15 HNRNPA1 NM_031157.4(HNRNPA1):c.1054C>T (p.Arg352Ter)SNV Uncertain significance 135606 rs483353037 12:54677742-54677742 12:54283958-54283958
16 HNRNPA1 NM_031157.4(HNRNPA1):c.1114T>C (p.Phe372Leu)SNV Likely benign 135615 rs483353043 12:54678092-54678092 12:54284308-54284308
17 HNRNPA1 NM_031157.4(HNRNPA1):c.1106G>A (p.Gly369Asp)SNV Likely benign 135613 rs483353042 12:54678084-54678084 12:54284300-54284300
18 HNRNPA1 NM_031157.4(HNRNPA1):c.1097A>G (p.Tyr366Cys)SNV Likely benign 135612 rs483353041 12:54678075-54678075 12:54284291-54284291
19 HNRNPA1 NM_031157.4(HNRNPA1):c.1078T>G (p.Ser360Ala)SNV Likely benign 135609 rs483353040 12:54678056-54678056 12:54284272-54284272

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 S100B MMP9 IL4 IL17A IL10 IFNG
2
Show member pathways
13.79 NGF IL4 IL17A IL10 CXCR3 CXCL10
3
Show member pathways
13.54 NGF IL4 IL17A IL10 IFNG IFNB1
4
Show member pathways
13.47 NGF IL4 IL17A IL10 IFNG IFNB1
5
Show member pathways
13.41 MMP9 CXCR3 CXCL10 CCR5 CCR3 CCR2
6
Show member pathways
13.33 MMP9 IL4 IL17A IL10 IFNG IFNB1
7
Show member pathways
13.33 NGF IL4 IL17A IL10 CXCR3 CXCL10
8
Show member pathways
13.11 MMP9 IL10 IFNG IFNB1 CXCL10 CCL2
9
Show member pathways
13.03 NGF IL4 IL17A IL10 CXCR3 CXCL10
10
Show member pathways
12.91 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
11
Show member pathways
12.85 IL4 IL17A IL10 IFNG CD40LG CCL21
12
Show member pathways
12.63 IL4 IL17A IL10 IFNG CD40LG CCR5
13 12.55 IL4 IL17A IL10 IFNG CXCL10 CD40LG
14
Show member pathways
12.39 MMP9 IL4 IL17A IFNG CXCL10 CCL2
15
Show member pathways
12.35 IL4 IL10 IFNG IFNB1
16
Show member pathways
12.34 IL10 CXCR3 CXCL10 CCR5 CCR3 CCR2
17
Show member pathways
12.32 IL4 IFNG CCL2 ALB
18
Show member pathways
12.3 NGF IL4 IL17A IL10 IFNG IFNB1
19
Show member pathways
12.29 IL4 IL10 IFNG CD40LG CCR5
20
Show member pathways
12.19 IL4 IFNG IFNB1 CXCL10
21 12.04 MMP9 IL4 IL17A IL10 CCL2
22 12 IL4 IL10 IFNG CCR3
23 11.98 MMP9 IFNB1 CXCL10 CCL2
24 11.94 IL10 IFNG IFNB1 CCR5 CCR2
25 11.84 IL4 IL17A IL10 IFNG CXCR3
26 11.77 S100B NGF BDNF
27
Show member pathways
11.75 IL4 IFNG CD40LG
28 11.74 IL10 IFNG IFNB1
29 11.69 MMP9 IL4 CCR3 CCR2 CCL2
30
Show member pathways
11.66 MMP9 IFNG CD40LG
31 11.66 IL4 IL10 CD40LG
32 11.64 MMP9 MBP IL4 IFNG CXCL10 CCR2
33 11.59 IL10 IFNG CD40LG CCL2
34 11.53 IFNG CCR2 CCL2
35 11.5 IL4 IL10 IFNG
36 11.49 NGF IL10 BDNF
37 11.49 IL4 IL10 CXCL10 CCR5 CCR2 CCL2
38 11.4 IFNG IFNB1 CXCL10
39 11.37 MMP9 CD40LG CCR2 CCL2
40 11.34 IL4 IFNG CD40LG
41 11.32 IL4 IL17A IFNG
42 11.32 IL4 IL10 IFNG IFNB1
43 11.22 MMP9 IFNG CCR3 CCL2
44 11.21 IL4 IL10 IFNG
45 11.08 MMP9 IL4 IL17A IL10 IFNG CXCL10
46 11.01 NGF IL4 IL17A IL10 CXCL10 CD40LG

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.8 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
2 extracellular region GO:0005576 9.8 S100B NGF MMP9 IL4 IL17A IL10
3 external side of plasma membrane GO:0009897 9.7 IL17A CXCR3 CXCL10 CD40LG CCR5 CCR3
4 extracellular space GO:0005615 9.47 S100B NGF MMP9 IL4 IL17A IL10

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 IL4 IL10 CXCR3 CXCL10 CD40LG CCR5
2 G protein-coupled receptor signaling pathway GO:0007186 10.19 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
3 negative regulation of apoptotic process GO:0043066 10.04 NGF MMP9 IL4 IL10 CD40LG ALB
4 cell-cell signaling GO:0007267 9.95 IL17A CXCL10 CCR5 CCL21
5 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 CXCL10 CCR5 CCL2
6 chemotaxis GO:0006935 9.91 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
7 cytokine-mediated signaling pathway GO:0019221 9.91 MMP9 IL4 IL17A IL10 IFNB1 CXCL10
8 positive regulation of cytosolic calcium ion concentration GO:0007204 9.9 CXCR3 CCR5 CCR3 CCR2
9 cell surface receptor signaling pathway GO:0007166 9.88 IFNG IFNB1 CXCR3 CXCL10 CCR5 CCL2
10 cell chemotaxis GO:0060326 9.87 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
11 memory GO:0007613 9.85 S100B NGF BDNF
12 neutrophil chemotaxis GO:0030593 9.84 CXCL10 CCL21 CCL2
13 cellular response to interleukin-1 GO:0071347 9.83 IL17A CCL21 CCL2
14 calcium-mediated signaling GO:0019722 9.83 CXCR3 CCR5 CCR3 CCR2
15 B cell differentiation GO:0030183 9.81 IL4 IL10 IFNB1 CD40LG
16 cellular defense response GO:0006968 9.8 CCR5 CCR3 CCR2
17 humoral immune response GO:0006959 9.78 IFNG IFNB1 CCR2 CCL2
18 monocyte chemotaxis GO:0002548 9.77 CCR2 CCL21 CCL2
19 B cell proliferation GO:0042100 9.73 IL10 IFNB1 CD40LG
20 JAK-STAT cascade GO:0007259 9.72 IFNG CCR2 CCL2
21 chemokine-mediated signaling pathway GO:0070098 9.7 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
22 T cell chemotaxis GO:0010818 9.67 CXCR3 CXCL10
23 dendritic cell chemotaxis GO:0002407 9.67 CCR5 CCR2 CCL21
24 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.65 MBP IL10
25 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.65 IL4 IL10
26 inflammatory response GO:0006954 9.65 IL17A IL10 CXCR3 CXCL10 CD40LG CCR5
27 positive regulation of collateral sprouting GO:0048672 9.64 NGF BDNF
28 positive regulation of receptor binding GO:1900122 9.63 MMP9 BDNF
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.63 IL4 IL10 IFNG
30 neuroinflammatory response GO:0150076 9.62 IL4 IFNG
31 type 2 immune response GO:0042092 9.61 IL4 IL10
32 positive regulation of interleukin-23 production GO:0032747 9.61 IL17A IFNG
33 positive regulation of NMDA glutamate receptor activity GO:1904783 9.61 IFNG CCR2 CCL2
34 positive regulation of cellular respiration GO:1901857 9.58 IL4 IFNG
35 regulation of isotype switching GO:0045191 9.58 IL4 IL10
36 immune response GO:0006955 9.44 MBP IL4 IL17A IL10 IFNG CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 S100B NGF MMP9 MBP IL4 IL17A
2 growth factor activity GO:0008083 9.73 NGF IL4 IL10 BDNF
3 chemokine activity GO:0008009 9.63 CXCL10 CCL21 CCL2
4 chemokine binding GO:0019956 9.62 CXCR3 CCR5 CCR3 CCR2
5 C-C chemokine binding GO:0019957 9.56 CXCR3 CCR5 CCR3 CCR2
6 C-C chemokine receptor activity GO:0016493 9.46 CXCR3 CCR5 CCR3 CCR2
7 CCR2 chemokine receptor binding GO:0031727 9.4 CCR2 CCL2
8 cytokine activity GO:0005125 9.28 IL4 IL17A IL10 IFNG IFNB1 CXCL10
9 chemokine receptor activity GO:0004950 9.26 CXCR3 CCR5 CCR3 CCR2

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....